SweetValueLab
Write for us

CRISPR Therapeutics AG — Financial Statements & Ratios

CRSP
NASDAQHealthcareBiotechnologyCIK 0001674416crisprtx.comAbout CRSP
Quant grade ?D
Last close · Oct 30, 202651.42−2.84 (−5.23%)

Key indicators

Revenue13.4MTTM−64.2% on a year earlier+1.7% a year, FY2018–FY2025
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTMFY2026EFY2027EFY2028E
Growth
3.1M 289.6M+9169.8%719,000−99.8%913.1M+126893.2%436,000−100.0%370.0M+84762.4%35.0M−90.5%3.5M−90.0%13.4M−64.2%40.4M 138.6M 518.0M
— 9169.8% -99.8% 126893.2% -100.0% 84762.4% -90.5% -90.0% -64.2% 1051.7% 242.8% 273.8%
-$3.44 $1.17+134.0%-$5.29−552.1%$4.70+188.8%-$8.36−277.9%-$1.94+76.8%-$4.34−123.7%-$6.47−49.1%-$4.71+13.3%-$4.36 -$3.33 -$2.01
Profitability
-3541.9% 38.1%+3580.0 pt-37369.7%−37407.7 pt88.9%+37458.6 pt-25186.7%−25275.6 pt64.8%+25251.5 pt-215.0%−279.8 pt-6537.0%−6322.0 pt-1546.6%−1316.8 pt· · ·
-5087.8% 16.1%+5103.9 pt-49295.5%−49311.7 pt40.9%+49336.5 pt-154394.7%−154435.6 pt-60.1%+154334.6 pt-1333.0%−1272.9 pt-16191.4%−14858.4 pt-3971.5%−2750.4 pt· · ·
-5281.1% 23.1%+5304.2 pt-48520.9%−48543.9 pt41.4%+48562.2 pt-149122.7%−149164.1 pt-41.5%+149081.2 pt-1046.4%−1004.9 pt-16569.8%−15523.3 pt-3368.7%−2116.6 pt· · ·
-42.1% 7.1%+49.2 pt-21.0%−28.1 pt15.7%+36.7 pt-34.7%−50.4 pt-8.2%+26.5 pt-19.0%−10.8 pt-30.3%−11.3 pt— · · ·
Cash
-99.0M 50.0M+150.5%-256.7M−613.5%457.3M+278.1%-532.9M−216.5%-269.8M+49.4%-144.7M+46.4%-345.9M−139.1%-373.8M−14.8%· · ·
-3169.4% 17.3%+3186.7 pt-35705.7%−35723.0 pt50.1%+35755.8 pt-122231.4%−122281.5 pt-72.9%+122158.5 pt-413.4%−340.4 pt-9855.5%−9442.1 pt-2791.2%−1919.7 pt· · ·
57,000 0−100.0%0 0 0 0 0 0 — · · ·
Balance sheet
0.00x 0.06x+0.06x0.04x−0.02x0.09x+0.06x0.13x+0.04x0.13x−0.00x0.12x−0.01x0.21x+0.09x0.45x+0.32x· · ·
47.96M 56.93M+18.7%65.95M+15.8%80.39M+21.9%77.75M−3.3%79.22M+1.9%84.36M+6.5%89.93M+6.6%96.51M+10.8%· · ·

E = analyst consensus (revenue and EPS only). TTM = the twelve months to Jun 30, 2026: the last fiscal year, plus the quarters since, less the same quarters a year earlier. From the 10-K and the 10-Qs since; the shaded column is the latest period.